COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).

Chromologic, Llc, Monrovia CA

Investigators

Abstract

The company proposes to develop a rapid clinical test using miRNA signatures to stratify patients diagnosed with COVID-19 by predicting likelihood of: 1) contracting ARDS related to COVID-19; 2) recovering from ARDS; or 3) mortality. The company has identified a panel of miRNAs from 240 normal and 22 ARDS patients, which was able to accurately (>98%) predict outcomes.